AstraZeneca PLC

ZEG

Company Profile

  • Business description

    A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

  • Contact

    1 Francis Crick Avenue
    Cambridge Biomedical Campus
    CambridgeCB2 0AA
    GBR

    T: +44 2037495000

    E: [email protected]

    https://www.astrazeneca.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    96,100

Stocks News & Analysis

stocks

Reassuring organic growth for undervalued ASX share

Efficiency gains are starting to make their mark.
stocks

Big IPOs are enticing but are they good investments?

Historically, buzzy debuts have been painful for buyers.
stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,692.80143.80-1.63%
CAC 407,950.07130.67-1.62%
DAX 4024,865.00598.81-2.35%
Dow JONES (US)49,203.91106.850.22%
FTSE 10010,367.5885.10-0.81%
HKSE22,410.80430.82-1.89%
NASDAQ23,400.98478.22-2.00%
Nikkei 22556,436.653,007.56-5.06%
NZX 50 Index14,107.41139.84-0.98%
S&P 5007,111.1164.72-0.90%
S&P/ASX 2008,592.60137.80-1.58%
SSE Composite Index3,533.7943.82-1.22%

Market Movers